Clinical trial
IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)
NCT00351949 · Immutep S.A.S., Industry · Completed
Key facts
| NCT number | NCT00351949 |
|---|---|
| Title | IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC) |
| Official title | IMP321 Phase 1 Study in Advanced or Metastatic Renal Cell Carcinoma Patients (P003) |
| Lead sponsor | Immutep S.A.S., Industry |
| Collaborators | Umanis Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Stage IV Renal Cell Carcinoma |
| Intervention type | Biological |
| Interventions | IMP321 |
| Enrollment | 24 |
| Start date | Sep 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jul 13, 2006 |
| Last update posted | Jan 7, 2010 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: